Korean Guidelines for Diagnosis and Management of Interstitial Lung Disease: Cryptogenic Organizing Pneumonia

Article information

Tuberc Respir Dis. 2025;88(3):477-487

Publication date (electronic) : 2025 March 13

doi : https://doi.org/10.4046/trd.2024.0167

Yong Suk Jo ¹

, Jong Sun Park ², Sun Hyo Park ³, Joon Sung Joh ⁴, Hye Jin Jang ⁵, Hyun-Kyung Lee^,⁶

, on behalf of Korean Interstitial Lung Disease Study Group

¹Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

²Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea

³Division of Pulmonology, Respiratory Center, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Republic of Korea

⁴Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Medical Center, Seoul, Republic of Korea

⁵Division of Pulmonology, Department of Internal Medicine, Inha University Hospital, Inha University College of Medicine, Incheon, Republic of Korea

⁶Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea

Address for correspondence Hyun-Kyung Lee Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, 75 Bokji-ro, Busanjin-gu, Busan 47392, Republic of Korea Phone 82-51-890-6847 Fax 82-51-890-6341 E-mail goodoc@gmail.com

Received 2024 November 4; Revised 2025 January 24; Accepted 2025 March 13.

Abstract

Cryptogenic organizing pneumonia (COP), one of the idiopathic interstitial pneumonias (IIP), exhibits an acute or subacute course. It can be diagnosed after excluding secondary causes or diseases. COP accounts for approximately 5% to 10% of IIPs, with the average age of diagnosis ranging from 50 to 60 years. Patients primarily present with dry cough and dyspnea. They often experience fever, fatigue, and weight loss. Common radiologic findings on high-resolution computed tomography include localized consolidations, which are typically subpleural or located in the lower zones, though they can occur in all regions of the lungs. While treatment can be initiated without histopathological diagnosis, tissue biopsy may be necessary when the diagnosis is unclear. Response to steroid therapy is generally good, with rapid clinical improvement and a favorable prognosis, although relapses are common.

Keywords: Interstitial Lung Disease; Cryptogenic Organizing Pneumonia; Guidelines

Introduction

In the 1980s, Davison et al. [1] and Epler et al. [2] described a condition characterized by cold-like symptoms persisting for 4 to 10 weeks with a histologic pattern of alveolar and alveolar duct organization. Although this condition responded well to steroids, it was prone to recurrence. They named this condition cryptogenic organizing pneumonia (COP) and bronchiolitis obliterans organizing pneumonia (BOOP), respectively. By 1997, idiopathic BOOP was recognized as an independent entity within the classification of idiopathic interstitial pneumonias (IIPs) by Muller and Colby. In 2002, a decision was made by the American Thoracic Society (ATS) and European Respiratory Society (ERS) to uniformly name it COP due to concerns that the term BOOP could be confused with airway diseases and that ‘organizing pneumonia (OP)’ was a generic term potentially applicable to various etiologies [3]. This classification was reaffirmed in the 2013 revision by the same societies, where COP continued to be the preferred term and secondary OP was described to be associated with specific causative conditions (e.g., rheumatoid arthritis-related OP) to differentiate it from idiopathic forms [4]. Diverse causes of secondary OP necessitate its exclusion before diagnosing COP.

Epidemiology

The precise incidence and prevalence of COP are unknown. However, a retrospective 20-year study in Iceland reported an incidence of 1.1 cases per 100,000 population [5] and a major teaching hospital in Canada observed a cumulative prevalence of 6.5 cases per 100,000 hospital admissions [6]. In interstitial lung disease (ILD) registries, the prevalence of COP was reported to be 5% in one study [7] and 10% in another [8]. A 2008 nationwide survey by the Korean Academy of Tuberculosis and Respiratory Diseases found that COP accounted for 8.5% of 2,186 patients with IIP, making it the third most common form of IIP in Korea [9]. With increasing recognition of various conditions that can cause OP, the diagnostic rate for COP is decreasing [10,11]. The average age at diagnosis of COP ranged from 50 to 60 years based on 37 studies involving 1,490 confirmed cases [9]. Reports have indicated no gender predominance, although some data suggest a slightly higher incidence in males. However, three studies on COP in Korea found a female predominance at approximately 60% [12-14]. Less than 15% were smokers and 54% were non-smokers, suggesting a low likelihood of association between COP and smoking [15,16].

Clinical Characteristics

COP should be considered in patients presumed to have infectious pneumonia when they do not respond to antibiotic treatment [15]. Clinically, symptoms manifest acutely or subacutely over weeks to months, usually beginning 2 months prior to diagnosis. The most common symptoms include a dry cough (71%) and dyspnea on exertion (62%). These symptoms can be accompanied by fever (44%), fatigue, malaise, and weight loss. Influenza-like symptoms such as nasal congestion, headache, chills, sweating, sore throat, cough, myalgia, and fever have been reported in 10% to 15% of cases, while the occurrence of hemoptysis is very rare (<5%). Some patients may rapidly progress to acute respiratory failure. Inspiratory crackles are detected in 60% of patients during auscultation, although some patients may present with normal breathing sounds [15,17-22].

Diagnosis

When diagnosing COP, it is crucial to differentiating it from other diseases with similar clinical presentations and to exclude potential causes of OP (Table 1) [15,16]. Community-acquired pneumonia is the most common and significant differential diagnosis. COP should be suspected if there is no response to antibiotic treatment. Radiologically, if multiple areas of pulmonary consolidation are observed, differential diagnoses such as hypersensitivity pneumonitis (HP), eosinophilic pneumonia, pulmonary hemorrhage, and vasculitis should be considered. When nodular consolidations with air bronchograms are observed, the possibility of pulmonary lymphoma or invasive mucinous adenocarcinoma should be considered. In cases where OP and nonspecific interstitial pneumonia (NSIP) occur concurrently or sequentially, differentiation is required for underlying causes such as connective tissue diseases (CTD), anti-synthetase syndrome, HP, and drug toxicity. A previous report has suggested an increased risk of disease progression when patterns of OP coexist with NSIP [23].

Table 1.

Potential causes of secondary organizing pneumonia

COP can be diagnosed and treated clinically without a tissue biopsy. However, if the diagnosis is ambiguous, a lung biopsy is necessary for confirmation. Such decision should be made through multidisciplinary discussion (Figure 1). In certain cases, causes of secondary OP, such as aspiration, vasculitis, and infection, may be identified through histological examination of lung biopsy sample. If treatment is initiated without a biopsy and if the clinical course and follow-up observations do not align with COP, a re-evaluation of the diagnosis is required, potentially necessitating a tissue biopsy [15,16].

Fig. 1.

Diagnostic algorithm for cryptogenic organizing pneumonia (COP) [16]. HRCT: high-resolution computed tomography; COVID-19: coronavirus disease 2019; CTD: connective tissue disease; HP: hypersensitivity pneumonitis; MDD: multidisciplinary discussion; UIP: usual interstitial pneumonia; BAL: bronchoalveolar lavage; ILD: interstitial lung disease; IPF: indiopathic pulmonary fibrosis.

1. Laboratory findings

Laboratory findings are nonspecific, with approximately half of patients showing elevated peripheral white blood cell counts, C-reactive protein, and erythrocyte sedimentation rate [18-22,24]. In cases of CTD, secondary OP can precede onset of the underlying disease by weeks to months. Therefore, when a CTD is clinically suspected, diagnostic tests for the underlying condition (e.g., antinuclear antibody, rheumatoid factor, anti-cyclic citrullinated peptide antibody, anti-dsDNA, CK, anti-centromere Ab, anti-Scl-70, and anti-Jo-1) should be considered [21].

2. Pulmonary function tests

Pulmonary function tests generally reveal restrictive ventilatory defects, with the forced vital capacity demonstrating a mild to moderate decrease ranging from 60% to 70%. Although airflow limitation is uncommon, it might be observed in ever-smokers. Approximately 25% of patients have normal lung volumes, while most exhibit a reduction in diffusing capacity of the lungs for carbon monoxide (DLco), which ranges from 50% to 70% of the predicted value. Even if pulmonary function is compromised at diagnosis, a good response to treatment can lead to normalization of these parameters [17,18,25].

3. Radiologic findings

The most common finding on chest high-resolution computed tomography (HRCT) is patchy pulmonary consolidation occurring peripherally (80% to 95%), typically without any signs of parenchymal destruction (Figure 2) [2,17,19,20,25-27]. These consolidations can occur in any pulmonary regions. They might affect either one lung or both, predominantly appearing subpleural or in the lower zones of the lungs. Consolidations often coincide with air bronchograms. They might be accompanied by ground-glass opacities and nodular patterns (Figure 3). Spontaneous resolution of pulmonary lesions and emergence of new lesions may coexist. The reverse halo sign, or atoll sign, characterized by a sclerotic rim surrounding a central area of transparency or ground-glass opacity, is observed in less than 5% of cases (Figure 4). Mediastinal lymph node enlargement is rare. A small amount of pleural effusion may occasionally be present [10,22,26,28-33]. Progressive fibrosis and honeycombing are exceedingly rare manifestations [33,34].

Fig. 2.

(A, B) Axial high-resolution computed tomography images showing peripheral and peribronchial distribution of air-space consolidation with ground-glass opacity in bilateral middle and lower lungs. Air bronchograms and mild cylindrical bronchiectasis (arrows in B) are commonly seen in areas of air-space consolidation.

Fig. 3.

(A, B) Axial high-resolution computed tomography images showing subpleural distribution of nodular opacities in both lungs. Air-bronchiolograms (arrow in A) and mild perinodular ground-glass opacity are also seen (arrow in B).

Fig. 4.

(A, B) Reversed halo (or atoll sign) is well shown on axial (A) and coronal (B) computed tomography images in a patient with organizing pneumonia pattern, which exhibits central area of ground-glass opacity with dense crescentic or ring-shaped periphery.

4. Bronchoscopy

Lymphocytes, plasma cells, and macrophages variably populate the interstitium. Bronchoalveolar lavage (BAL) fluid cytology commonly reveals an increase in the lymphocyte fraction exceeding 25%. Although CD4/CD8 ratio is usually decreased, this finding is nonspecific. Increases in neutrophils and eosinophils can also occur. An increase in neutrophils necessitates ruling out infectious diseases, while an increase in eosinophils suggests a need to differentiate eosinophilic pneumonia Furthermore, BAL is recommended to exclude infectious diseases, pulmonary hemorrhage, and other conditions [12,13,25,28,35-38].

5. Lung biopsy and histologic features

Histologically, granulation tissue (Masson’s bodies) is typically observed within the alveoli, alveolar ducts, and occasionally in small bronchioles, sometimes accompanied by intraluminal bronchiolar polyps (Figure 5). These features are characteristic of OP, which often displays a patchy distribution without significant alteration of lung architecture [39]. Interstitial fibrosis, granulomas, necrosis, vasculitis, and hyaline membranes are rare findings that might suggest other diseases [38]. While surgical lung biopsy remains the standard, studies have also diagnosed OP using transbronchial lung biopsy. A study involving 37 subjects reported a diagnostic sensitivity of 64% and a specificity of 86% for this method [40]. Several retrospective studies have reported improvement after steroid therapy by observing the pattern of OP through transbronchial lung biopsy [19]. Some studies have suggested that a diagnosis can also be made through percutaneous transthoracic needle biopsy [41]. Recent advancements in transbronchial lung cryobiopsy (TBLC) have shown high concordance with surgical lung biopsies in diagnosing ILD [42], suggesting that TBLC could be beneficial for diagnosing COP. Further validation of TBLC in COP is warranted.

Fig. 5.

Organizing pneumonia pattern. Photomicrography of transbronchial lung biopsy shows several intra-alveolar f ibroblastic plugs (arrows). Mild interstitial lymphoid cell infiltration is accompanied (H&E, ×100).

Treatment

1. Expert recommendation

- Steroids may be utilized in the treatment of COP (voting result: strong recommendation from five out of six experts)

- In patients with COP, immunosuppressive therapy may be considered in cases of progression or recurrence despite steroid monotherapy (voting result: conditional recommendation from six out of six experts).

2. Steroid

To date, there are no controlled studies comparing steroids with placebo in the treatment of COP. However, many studies have reported rapid clinical improvement with steroid therapy in COP [15]. The initial dosing starts at prednisone 0.5–1 mg/kg per day, with a maximum of 60 mg daily for 2 to 4 weeks as a single oral dose. Depending on the clinical response, the dosage is gradually tapered over 4 to 6 months. Although not well studied, treatment duration is generally recommended to be between 6 months and 1 year [17,27]. Patients who respond well to treatment often show clinical improvement within 24–72 hours. Complete remission may be confirmed after 3 months [27]. For patients using more than 20 mg/day of prednisone, prophylaxis against Pneumocystis jirovecii is recommended [15]. In cases of severe and rapidly progressing disease where respiratory failure is emergent, high-dose steroid pulse therapy with methylprednisolone 500 to 1,000 mg intravenously for 3 to 5 days may be necessary, with a switch to oral therapy within a few days as the patient improves [31].

To reduce the risk of cumulative steroid dosage and side effects, a previous study has introduced a regimen starting with prednisone at 0.75 mg/kg/day for 4 weeks, followed by 0.5 mg/kg/day for another 4 weeks, then 20 mg/day for 4 weeks, 10 mg/day for 6 weeks, and finally 5 mg/day for another 6 weeks, totaling 24 weeks. At this dose regimen, the disease course did not differ compared to patients treated with other regimens, while the cumulative steroid dosage was reduced by 50% [16].

Recurrences also respond well to steroids. A study comparing outcomes between increasing the dose to 20 mg/day of prednisone when relapses occur under a dose of 20 mg/day or less versus increasing to higher doses (average 40 mg/day) found no difference in clinical outcomes, with higher doses leading to more side effects [27]. Based on this, it could be reasonable to reinitiate treatment with prednisone at 20 mg/day and taper the dose in case of recurrence.

3. Macrolide antibiotics

Small retrospective observational studies have reported that macrolide antibiotics (erythromycin, azithromycin, or clarithromycin), known for their anti-inflammatory properties, can serve as adjuvants to oral steroids [21,35]. It has been reported that macrolides could be an alternative to steroids in patients with mild COP who have normal lung function due to their shorter treatment durations, lower side effects (such as upper respiratory infections and weight gain), and lower relapse rates than steroids [43]. In one of these studies, clarithromycin was administered orally at a dose of 500 mg twice daily for 3 months. The steroid group used prednisone, with an average initial dose of 0.67±0.24 mg/kg/day, administered over an average of 8.59±3.05 months [43]. Other studies have compared the combined therapy of macrolides and steroids to steroid monotherapy [21,43,44]. The combination treatment (clarithromycin 100 mg/day for 1 week, 500 mg/day for 3 weeks, 250 mg/day for 8 weeks, total 12 weeks, accompanied by prednisone 0.75 mg/kg/day for 2 weeks, 0.5 mg/kg/day for 2 weeks, 20 mg/day for 2 weeks, 10 mg/day for 3 weeks, 5 mg/day for 3 weeks, total 12 weeks) did not demonstrate superiority over steroid monotherapy (prednisone 0.75 mg/kg/day for 4 weeks, 0.5 mg/kg/day for 4 weeks, 20 mg/day for 4 weeks, 10 mg/day for 6 weeks, 5 mg/day for 6 weeks, total 24 weeks), showing a lower response rate and a higher relapse rate. Therefore, the role of macrolides in the treatment of COP has not yet been conclusively determined [16].

4. Other medications

Immunoglobulin [45], rituximab [46], cyclophosphamide [47], and mycophenolic acid [48] are being explored as alternatives or for their steroid-sparing effects in severe cases of COP that do not respond to steroids. However, their effectiveness remains unclear as it has only been documented in case reports.

Natural Course and Prognosis

In some cases, COP improves naturally without pharmacological treatment and generally responds well to steroid therapy, with most patients achieving complete recovery. Improvement is usually rapid within days after starting steroids, although occasionally it can take more than 10 days, with most imaging findings showing improvement after 3 months [13,14,28]. Follow-up HRCT shows that while pulmonary consolidation may partially or completely resolve, reticular opacities may persist or progress, potentially leading to fibrotic sequelae. One study has reported that initial poor responses to treatment are associated with cases showing traction bronchiectasis or extensive pulmonary consolidation affecting more than 10% of the lung area on initial chest computed tomography scans, with secondary OP typically showing poorer responses than idiopathic cases [13].

Progressive respiratory failure is rare. Most retrospective studies have reported that mortality due to COP occurs in less than 10% of cases, with a 5-year survival rate of over 90%. Most deaths are due to underlying diseases in cases of secondary OP [12,14,23,24,27-29,49]. Cohen et al. [34] have analyzed outcomes of 10 patients with BOOP showing progressive pulmonary fibrosis and found that most of them have drug or environmental exposures or secondary OP due to CTD [24,34].

Recurrences are relatively common, with reported relapse rates ranging from 13% to 70% [16]. Most recurrences occur within the first year of treatment, often upon tapering or discontinuation of steroids. Risks of relapse are higher if treatment is delayed after symptom onset, if initial steroid doses are low or the duration of use is short, or if pulmonary consolidation is extensive [23,24,27-29,43]. If relapse occurs while taking more than 20 mg of prednisone or after 18 months from the onset, the diagnosis of COP should be reconsidered and the possibility of CTD, HP, and drug-induced secondary OP should be evaluated [16].

Acute Fibrous and Organizing Pneumonia

Acute fibrous and organizing pneumonia (AFOP) was first described in 2002 by Beasley et al. [50] as a histological subtype of IIP. Unlike diffuse alveolar damage, which exhibits similar rapid and progressive lung injury, or OP, AFOP is characterized by distinctive intra-alveolar fibrin deposition, alongside acute and chronic inflammation of the adjacent pulmonary parenchyma and proliferation of type II pneumocytes (Figure 6) [50,51]. Radiographically, it often presents as bilateral pulmonary consolidations, predominantly in the lower lobes, with reticular and reticulonodular interstitial shadow (Figure 7) [52]. In 2013, the ATS/ERS guidelines on ILD recognized AFOP as a rare type of IIP [4].

Fig. 6.

Acute fibrinous organizing pneumonia. Photomicrography of explanted lung specimen shows many ovoidshaped aggregates of fibrin, acute inflammatory cells, and macrophages filling airspaces (arrows). Alveolar septa display near-total denudation of alveolar pneumocytes with diffuse fibroblastic proliferation (arrowheads), which indicates diffuse alveolar damage (H&E, ×100).

Fig. 7.

(A, B) Axial high-resolution computed tomography images showing diffuse ground-glass opacity in the periphery of both upper lobes (A) and basilar dependent air-space consolidation (B), similar to findings of an organizing pneumonia pattern.

AFOP has been reported in patients with a wide age range from 38 to 80 years. It is clinically characterized by rapidly progressive respiratory failure [51,53,54]. Its mortality rate is approximately 50%, with about 30% of cases requiring mechanical ventilation. However, some cases of AFOP have shown a favorable prognosis [50,55,56]. A recent study found that among 15 patients with surgically confirmed AFOP, nine (60%) required mechanical ventilation and eight (53%) died [57]. Among survivors, five showed significant improvement [57]. Rapidly progressing dyspnea, severe hypoxemia, and bilateral pulmonary infiltrates should prompt differential diagnosis between acute interstitial pneumonia (AIP) and AFOP, with consideration for a lung biopsy for confirmation. Initially, fever may accompany symptoms, making it challenging to differentiate it from infectious diseases such as pneumonia. Like COP, secondary AFOP has been frequently associated with various causes, including infections, CTD, hematological malignancies, and drugs (e.g., programmed death-ligand 1 inhibitors, amiodarone), making it crucial to identifying triggering factors [50,58].

Treatment for severe, rapidly progressing cases may follow protocols for AIP, including high-dose steroid pulse therapy with methylprednisolone at 1 mg/kg or 1,000 mg for 3 days [56]. In cases unresponsive to steroids, cyclophosphamide or mycophenolate mofetil could be used [59].

Notes

Authors’ Contributions

Conceptualization: all authors. Methodology: all authors. Formal analysis: all authors. Software: all authors. Validation: all authors. Investigation: all authors. Writing - original draft preparation: Jo YS. Writing - review and editing: all authors. Approval of final manuscript: all authors.

Conflicts of Interest

Yong Suk Jo is an editor and Hye Jin Jang is an early career editorial board member of the journal, but they were not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.

Funding

No funding to declare.

References

1. Davison AG, Heard BE, McAllister WA, Turner-Warwick ME. Cryptogenic organizing pneumonitis. Q J Med 1983;52:382–94.

2. Epler GR, Colby TV, McLoud TC, Carrington CB, Gaensler EA. Bronchiolitis obliterans organizing pneumonia. N Engl J Med 1985;312:152–8.

3. American Thoracic Society, ; European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277–304.

4. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733–48.

5. Gudmundsson G, Sveinsson O, Isaksson HJ, Jonsson S, Frodadottir H, Aspelund T. Epidemiology of organising pneumonia in Iceland. Thorax 2006;61:805–8.

6. Alasaly K, Muller N, Ostrow DN, Champion P, FitzGerald JM. Cryptogenic organizing pneumonia: a report of 25 cases and a review of the literature. Medicine (Baltimore) 1995;74:201–11.

7. Karakatsani A, Papakosta D, Rapti A, Antoniou KM, Dimadi M, Markopoulou A, et al. Epidemiology of interstitial lung diseases in Greece. Respir Med 2009;103:1122–9.

8. Xaubet A, Ancochea J, Morell F, Rodriguez-Arias JM, Villena V, Blanquer R, et al. Report on the incidence of interstitial lung diseases in Spain. Sarcoidosis Vasc Diffuse Lung Dis 2004;21:64–70.

9. Scientific Committee of the Korean Academy of Tuberculosis and Respiratory Diseases. 2009 National survey of idiopathic interstitial pneumonia in Korea. Tuberc Respir Dis 2009;66:141–51.

10. Zhang Y, Li N, Li Q, Zhou Y, Zhang F, Chen T, et al. Analysis of the clinical characteristics of 176 patients with pathologically confirmed cryptogenic organizing pneumonia. Ann Transl Med 2020;8:763.

11. Vieira AL, Vale A, Melo N, Caetano Mota P, Jesus JM, Cunha R, et al. Organizing pneumonia revisited: insights and uncertainties from a series of 67 patients. Sarcoidosis Vasc Diffuse Lung Dis 2018;35:129–38.

12. Yoo JW, Song JW, Jang SJ, Lee CK, Kim MY, Lee HK, et al. Comparison between cryptogenic organizing pneumonia and connective tissue disease-related organizing pneumonia. Rheumatology (Oxford) 2011;50:932–8.

13. Cho YH, Chae EJ, Song JW, Do KH, Jang SJ. Chest CT imaging features for prediction of treatment response in cryptogenic and connective tissue disease-related organizing pneumonia. Eur Radiol 2020;30:2722–30.

14. Chung MP, Nam BD, Lee KS, Han J, Park JS, Hwang JH, et al. Serial chest CT in cryptogenic organizing pneumonia: evolutional changes and prognostic determinants. Respirology 2018;23:325–30.

15. King TE Jr, Lee JS. Cryptogenic organizing pneumonia. N Engl J Med 2022;386:1058–69.

16. Raghu G, Meyer KC. Cryptogenic organising pneumonia: current understanding of an enigmatic lung disease. Eur Respir Rev 2021;30:210094.

17. Lohr RH, Boland BJ, Douglas WW, Dockrell DH, Colby TV, Swensen SJ, et al. Organizing pneumonia. Features and prognosis of cryptogenic, secondary, and focal variants. Arch Intern Med 1997;157:1323–9.

18. Boots RJ, McEvoy JD, Mowat P, Le Fevre I. Bronchiolitis obliterans organising pneumonia: a clinical and radiological review. Aust N Z J Med 1995;25:140–5.

19. Barroso E, Hernandez L, Gil J, Garcia R, Aranda I, Romero S. Idiopathic organizing pneumonia: a relapsing disease: 19 years of experience in a hospital setting. Respiration 2007;74:624–31.

20. Izumi T, Kitaichi M, Nishimura K, Nagai S. Bronchiolitis obliterans organizing pneumonia: clinical features and differential diagnosis. Chest 1992;102:715–9.

21. Zhou Y, Wang L, Huang M, Ding J, Jiang H, Zhou K, et al. A long-term retrospective study of patients with biopsy-proven cryptogenic organizing pneumonia. Chron Respir Dis 2019;16:1479973119853829.

22. Choi KJ, Yoo EH, Kim KC, Kim EJ. Comparison of clinical features and prognosis in patients with cryptogenic and secondary organizing pneumonia. BMC Pulm Med 2021;21:336.

23. Todd NW, Marciniak ET, Sachdeva A, Kligerman SJ, Galvin JR, Luzina IG, et al. Organizing pneumonia/non-specific interstitial pneumonia overlap is associated with unfavorable lung disease progression. Respir Med 2015;109:1460–8.

24. Watanabe K, Senju S, Wen FQ, Shirakusa T, Maeda F, Yoshida M. Factors related to the relapse of bronchiolitis obliterans organizing pneumonia. Chest 1998;114:1599–606.

25. King TE Jr, Mortenson RL. Cryptogenic organizing pneumonitis: the North American experience. Chest 1992;1021 Suppl. :8S–13S.

26. Sveinsson OA, Isaksson HJ, Sigvaldason A, Yngvason F, Aspelund T, Gudmundsson G. Clinical features in secondary and cryptogenic organizing pneumonia. Int J Tuberc Lung Dis 2007;11:689–94.

27. Lazor R, Vandevenne A, Pelletier A, Leclerc P, Court-Fortune I, Cordier JF. Cryptogenic organizing pneumonia: characteristics of relapses in a series of 48 patients. Am J Respir Crit Care Med 2000;162(2 Pt 1):571–7.

28. Yamamoto M, Ina Y, Kitaichi M, Harasawa M, Tamura M. Clinical features of BOOP in Japan. Chest 1992;102(1 Suppl):21S–5S.

29. Vasu TS, Cavallazzi R, Hirani A, Sharma D, Weibel SB, Kane GC. Clinical and radiologic distinctions between secondary bronchiolitis obliterans organizing pneumonia and cryptogenic organizing pneumonia. Respir Care 2009;54:1028–32.

30. Pardo J, Panizo A, Sola I, Queipo F, Martinez-Penuela A, Carias R. Prognostic value of clinical, morphologic, and immunohistochemical factors in patients with bronchiolitis obliterans-organizing pneumonia. Hum Pathol 2013;44:718–24.

31. Saito Z, Kaneko Y, Hasegawa T, Yoshida M, Odashima K, Horikiri T, et al. Predictive factors for relapse of cryptogenic organizing pneumonia. BMC Pulm Med 2019;19:10.

32. Ujita M, Renzoni EA, Veeraraghavan S, Wells AU, Hansell DM. Organizing pneumonia: perilobular pattern at thin-section CT. Radiology 2004;232:757–61.

33. Lee KS, Kullnig P, Hartman TE, Muller NL. Cryptogenic organizing pneumonia: CT findings in 43 patients. AJR Am J Roentgenol 1994;162:543–6.

34. Cohen AJ, King TE Jr, Downey GP. Rapidly progressive bronchiolitis obliterans with organizing pneumonia. Am J Respir Crit Care Med 1994;149:1670–5.

35. Drakopanagiotakis F, Paschalaki K, Abu-Hijleh M, Aswad B, Karagianidis N, Kastanakis E, et al. Cryptogenic and secondary organizing pneumonia: clinical presentation, radiographic findings, treatment response, and prognosis. Chest 2011;139:893–900.

36. Nagai S, Aung H, Tanaka S, Satake N, Mio T, Kawatani A, et al. Bronchoalveolar lavage cell findings in patients with BOOP and related diseases. Chest 1992;102(1 Suppl):32S–7S.

37. Jara-Palomares L, Gomez-Izquierdo L, Gonzalez-Vergara D, Rodriguez-Becerra E, Marquez-Martin E, Barrot-Cortes E, et al. Utility of high-resolution computed tomography and BAL in cryptogenic organizing pneumonia. Respir Med 2010;104:1706–11.

38. Olopade CO, Crotty TB, Douglas WW, Colby TV, Sur S. Chronic eosinophilic pneumonia and idiopathic bronchiolitis obliterans organizing pneumonia: comparison of eosinophil number and degranulation by immunofluorescence staining for eosinophil-derived major basic protein. Mayo Clin Proc 1995;70:137–42.

39. Guerry-Force ML, Muller NL, Wright JL, Wiggs B, Coppin C, Pare PD, et al. A comparison of bronchiolitis obliterans with organizing pneumonia, usual interstitial pneumonia, and small airways disease. Am Rev Respir Dis 1987;135:705–12.

40. Poletti V, Cazzato S, Minicuci N, Zompatori M, Burzi M, Schiattone ML. The diagnostic value of bronchoalveolar lavage and transbronchial lung biopsy in cryptogenic organizing pneumonia. Eur Respir J 1996;9:2513–6.

41. Miao L, Wang Y, Li Y, Ding J, Chen L, Dai J, et al. Lesion with morphologic feature of organizing pneumonia (OP) in CT-guided lung biopsy samples for diagnosis of bronchiolitis obliterans organizing pneumonia (BOOP): a retrospective study of 134 cases in a single center. J Thorac Dis 2014;6:1251–60.

42. Troy LK, Grainge C, Corte TJ, Williamson JP, Vallely MP, Cooper WA, et al. Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. Lancet Respir Med 2020;8:171–81.

43. Radzikowska E, Wiatr E, Langfort R, Bestry I, Skoczylas A, Szczepulska-Wojcik E, et al. Cryptogenic organizing pneumonia: results of treatment with clarithromycin versus corticosteroids: observational study. PLoS One 2017;12e0184739.

44. Petitpierre N, Cottin V, Marchand-Adam S, Hirschi S, Rigaud D, Court-Fortune I, et al. A 12-week combination of clarithromycin and prednisone compared to a 24-week prednisone alone treatment in cryptogenic and radiation-induced organizing pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2018;35:230–8.

45. Dimala CA, Patel U, Lloyd B, Donato A, Kimmel WB, Hallowell R, et al. A case report of steroid-resistant cryptogenic organizing pneumonia managed with intravenous immunoglobulins. Case Rep Pulmonol 2021;2021:9343491.

46. Loftis CE, Dulgheru E, Kaplan A. Rituximab for steroid-resistant organizing pneumonia in a woman with rheumatoid arthritis. BMJ Case Rep 2022;15e249912.

47. Schulze AB, Evers G, Kummel A, Rosenow F, Sackarnd J, Hering JP, et al. Cyclophosphamide pulse therapy as treatment for severe interstitial lung diseases. Sarcoidosis Vasc Diffuse Lung Dis 2019;36:157–66.

48. Paul C, Lin-Shaw A, Joseph M, Kwan K, Sergiacomi G, Mura M. Successful treatment of fibrosing organising pneumonia causing respiratory failure with mycophenolic acid. Respiration 2016;92:279–82.

49. Baha A, Yildirim F, Kokturk N, Galata Z, Akyurek N, Demirci NY, et al. Cryptogenic and secondary organizing pneumonia: clinical presentation, radiological and laboratory findings, treatment, and prognosis in 56 cases. Turk Thorac J 2018;19:201–8.

50. Beasley MB, Franks TJ, Galvin JR, Gochuico B, Travis WD. Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage. Arch Pathol Lab Med 2002;126:1064–70.

51. Santos C, Oliveira RC, Serra P, Baptista JP, Sousa E, Casanova P, et al. Pathophysiology of acute fibrinous and organizing pneumonia: clinical and morphological spectra. Pathophysiology 2019;26:213–7.

52. Lee JH, Yum HK, Jamous F, Santos C, Campisi A, Surani S, et al. Diagnostic procedures and clinico-radiological findings of acute fibrinous and organizing pneumonia: a systematic review and pooled analysis. Eur Radiol 2021;31:7283–94.

53. Kim JY, Doo KW, Jang HJ. Acute fibrinous and organizing pneumonia: imaging features, pathologic correlation, and brief literature review. Radiol Case Rep 2018;13:867–70.

54. Onishi Y, Kawamura T, Higashino T, Mimura R, Tsukamoto H, Sasaki S. Clinical features of acute fibrinous and organizing pneumonia: an early histologic pattern of various acute inflammatory lung diseases. PLoS One 2021;16e0249300.

55. Dai JH, Li H, Shen W, Miao LY, Xiao YL, Huang M, et al. Clinical and radiological profile of acute fibrinous and organizing pneumonia: a retrospective study. Chin Med J (Engl) 2015;128:2701–6.

56. Gomes R, Padrao E, Dabo H, Soares Pires F, Mota P, Melo N, et al. Acute fibrinous and organizing pneumonia: a report of 13 cases in a tertiary university hospital. Medicine (Baltimore) 2016;95e4073.

57. Kim MC, Kim YW, Kwon BS, Kim J, Lee YJ, Cho YJ, et al. Clinical features and long-term prognosis of acute fibrinous and organizing pneumonia histologically confirmed by surgical lung biopsy. BMC Pulm Med 2022;22:56.

58. Perez Perez JL, Gaya Garcia-Manso I, Garcia Sevila R. Acute fibrinous and organizing pneumonia associated with immunotherapy (pembrolizumab). Arch Bronconeumol 2022;58:425–6.

59. Garcia-Huertas D, Lopez-Fernandez A, De Dios-Chacon I. Acute fibrinous and organizing pneumonia. Med Clin (Engl Ed) 2022;158:144–5.

Article information Continued

It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).